Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 2
2008 1
2009 2
2010 1
2011 4
2012 1
2013 2
2014 5
2015 3
2016 4
2017 9
2018 9
2019 8
2020 4
2021 2
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

52 results
Results by year
Filters applied: . Clear all
Page 1
Safety and dose modification for patients receiving niraparib.
Berek JS, Matulonis UA, Peen U, Ghatage P, Mahner S, Redondo A, Lesoin A, Colombo N, Vergote I, Rosengarten O, Ledermann J, Pineda M, Ellard S, Sehouli J, Gonzalez-Martin A, Berton-Rigaud D, Madry R, Reinthaller A, Hazard S, Guo W, Mirza MR. Berek JS, et al. Among authors: berton rigaud d. Ann Oncol. 2018 Aug 1;29(8):1784-1792. doi: 10.1093/annonc/mdy181. Ann Oncol. 2018. PMID: 29767688 Free article. Clinical Trial.
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
Mirza MR, Benigno B, Dørum A, Mahner S, Bessette P, Barceló IB, Berton-Rigaud D, Ledermann JA, Rimel BJ, Herrstedt J, Lau S, du Bois A, Herráez AC, Kalbacher E, Buscema J, Lorusso D, Vergote I, Levy T, Wang P, de Jong FA, Gupta D, Matulonis UA. Mirza MR, et al. Among authors: berton rigaud d. Gynecol Oncol. 2020 Nov;159(2):442-448. doi: 10.1016/j.ygyno.2020.09.006. Epub 2020 Sep 25. Gynecol Oncol. 2020. PMID: 32981695 Clinical Trial.
Traitement des rechutes tardives du cancer de l’ovaire.
Floquet A, Berton-Rigaud D, Ferron G, Freyer G, Hardy-Bessard AC, You B. Floquet A, et al. Among authors: berton rigaud d. Bull Cancer. 2017 May;104 Suppl 1:S24-S31. doi: 10.1016/S0007-4551(17)30159-5. Bull Cancer. 2017. PMID: 28625312 French.
Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study.
Ott PA, Bang YJ, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS, Puzanov I, Mehnert JM, Aung KL, Lopez J, Carrigan M, Saraf S, Chen M, Soria JC. Ott PA, et al. Among authors: berton rigaud d. J Clin Oncol. 2017 Aug 1;35(22):2535-2541. doi: 10.1200/JCO.2017.72.5952. Epub 2017 May 10. J Clin Oncol. 2017. PMID: 28489510 Clinical Trial.
Pertuzumab for the treatment of breast cancer.
Robert M, Frenel JS, Bourbouloux E, Berton Rigaud D, Patsouris A, Augereau P, Gourmelon C, Campone M. Robert M, et al. Among authors: berton rigaud d. Expert Rev Anticancer Ther. 2020 Feb;20(2):85-95. doi: 10.1080/14737140.2019.1596805. Epub 2019 Aug 29. Expert Rev Anticancer Ther. 2020. PMID: 30884986 Review.
Pharmacokinetic drug evaluation of abemaciclib for advanced breast cancer.
Robert M, Frenel JS, Bourbouloux E, Berton Rigaud D, Patsouris A, Augereau P, Gourmelon C, Campone M. Robert M, et al. Among authors: berton rigaud d. Expert Opin Drug Metab Toxicol. 2019 Feb;15(2):85-91. doi: 10.1080/17425255.2019.1559816. Epub 2019 Jan 5. Expert Opin Drug Metab Toxicol. 2019. PMID: 30577708 Review.
[Her2 positive breast cancer: practices].
Campone M, Berton-Rigaud D, Bourbouloux E, Sophie S, Zanetti A, Frenel JS. Campone M, et al. Among authors: berton rigaud d. Bull Cancer. 2011 Feb;98(2):154-63. Bull Cancer. 2011. PMID: 21591301 Free article. Review. French.
Lapatinib in metastatic breast cancer.
Frenel JS, Bourbouloux E, Berton-Rigaud D, Sadot-Lebouvier S, Zanetti A, Campone M. Frenel JS, et al. Among authors: berton rigaud d. Womens Health (Lond). 2009 Nov;5(6):603-12. doi: 10.2217/whe.09.54. Womens Health (Lond). 2009. PMID: 19863462 Free article. Review.
Menopausal symptoms in epithelial ovarian cancer survivors: a GINECO VIVROVAIRE2 study.
Gernier F, Gompel A, Rousset-Jablonski C, Kalbacher E, Floquet A, Berton-Rigaud D, Tredan O, Alexandre J, Follana P, Zannetti A, Dohollou N, Grellard JM, Clarisse B, Licaj I, Ahmed-Lecheheb D, Fauvet R, Pautier P, Joly F. Gernier F, et al. Among authors: berton rigaud d. Gynecol Oncol. 2021 Dec;163(3):598-604. doi: 10.1016/j.ygyno.2021.10.001. Epub 2021 Oct 11. Gynecol Oncol. 2021. PMID: 34649724 Free article.
Benefits versus risk profile of buparlisib for the treatment of breast cancer.
Patsouris A, Augereau P, Frenel JS, Robert M, Gourmelon C, Bourbouloux E, Berton-Rigaud D, Chevalier LM, Campone M. Patsouris A, et al. Among authors: berton rigaud d. Expert Opin Drug Saf. 2019 Jul;18(7):553-562. doi: 10.1080/14740338.2019.1623877. Expert Opin Drug Saf. 2019. PMID: 31159599 Review.
52 results